Cellectis (CLLS) Capital Expenditures Growth (1y) (2016 - 2026)
Cellectis (CLLS) Capital Expenditures Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn | -27.93% |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - | - |
| 10 | Cellectis | 288.51 Mn | 102.85 Mn | - | 32.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.91% |
| Dec 31, 2025 | -8.12% |
| Sep 30, 2025 | -51.99% |
| Jun 30, 2025 | 70.62% |
| Mar 31, 2025 | -81.19% |
| Dec 31, 2024 | 146.84% |
| Sep 30, 2024 | -147.45% |
| Jun 30, 2024 | -284.44% |
| Mar 31, 2024 | -2.35% |
| Dec 31, 2023 | -57.69% |
| Sep 30, 2023 | 29.91% |
| Jun 30, 2023 | 70.49% |
| Mar 31, 2023 | 65.97% |
| Dec 31, 2022 | -87.99% |
| Sep 30, 2022 | 90.29% |
| Jun 30, 2022 | 83.21% |
| Mar 31, 2022 | 92.36% |
| Dec 31, 2021 | -49.11% |
| Sep 30, 2021 | 27.18% |
| Jun 30, 2021 | 61.01% |